The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes

Clinical and Translational Medicine

Table 2 Differentially expressed genes in cardiomyocytes following ERBB2 inhibition

Gene	logCPM	iPSC cardiomyocytes treated with trastuzumab		iPSC cardiomyoytes treated with lapatinib
Gene	logCPM	FC	p value	FC	p value
PHLDA1	4.366	0.53	0.003	0.29	8.89E−09
SLC6A6	3.051	0.53	0.006	0.27	2.35E−08
RGS4	1.850	0.66	0.022	0.41	1.15E−06
LDLR	5.843	0.66	0.007	0.48	1.98E−06
RP11-290L1.3	2.017	0.44	0.004	0.26	3.09E−06
FSTL5	1.461	2.26	2.25576E−05	2.23	2.93E−05
EGR1	3.271	0.40	6.21035E−05	0.39	4.71E−05
KRT6A	−1.435	0.00	1.51E−04	0.00	1.42E−04
STK32A	1.068	1.97	6.48E−04	2.08	2.05E−04
PRRT4	2.336	1.72	2.62E−04	1.68	4.71E−04
FAM71F2	0.724	1.91	0.007	2.22	0.001
ZNF483	1.654	1.76	0.018	2.22	0.001
ACRC	0.475	1.65	0.025	2.09	0.001
RP11-285F7.2	0.797	1.66	0.020	2.03	0.001
LINC00842	3.506	1.64	0.001	1.61	0.002
RP3-434O14.8	0.954	2.14	0.001	1.97	0.002
NFASC	0.677	1.58	0.048	1.99	0.002
PMCH	0.823	0.64	0.047	0.51	0.003
CAV3	0.797	1.58	0.027	1.81	0.004
AL132989.1	0.577	2.04	0.012	2.18	0.006
SDC1	1.833	0.62	0.013	0.60	0.007
SLC28A1	1.089	1.96	0.028	2.25	0.008
KIAA1107	2.568	1.54	0.028	1.68	0.008
PLK3	0.683	0.55	0.006	0.56	0.009
SLC7A7	1.628	2.00	1.39564E−05	1.51	0.011
GRM8	0.678	1.92	0.011	1.89	0.012
NPY4R	0.487	1.85	0.032	2.06	0.012
FAM110A	1.255	0.64	0.011	0.66	0.016
GFAP	1.856	0.62	0.006	0.66	0.017
APBB1IP	0.323	2.46	0.003	2.06	0.019
IL31RA	0.956	3.85	1.56156E−06	1.94	0.020
RPP25	2.028	0.65	0.045	0.61	0.020
AC007036.5	2.769	1.64	0.023	1.66	0.020
LINC00327	0.750	1.59	0.009	1.51	0.021
PKN3	2.451	0.65	0.024	0.66	0.024
MTFP1	2.980	0.64	0.037	0.62	0.026
PROM1	1.535	1.69	0.010	1.55	0.031
ATF4P3	1.473	0.58	0.007	0.66	0.038

Overlap of trastuzumab and lapatinib differentially expressed genes in cardiomyocytes, fold change >1.5, p < 0.05
iPSC induced pluripotent stem cell, FC fold change